Neurovascular devices market seen reaching $10.48 billion by 2035

Market Research Future projects the global neurovascular devices market will grow from $5.56 billion in 2026 to $10.48 billion by 2035, driven by expanded stroke-treatment guidelines, broader reimbursement and robotic catheter navigation. The forecast points to rising demand across hospitals, ambulatory centers and major regions, especially North America and Asia-Pacific. Why it matters: - The forecast signals sustained demand for minimally invasive stroke and cerebrovascular treatment tools through 2035. - Growth is being powered by changes in clinical guidelines, reimbursement and hospital technology spending, not by optional elective demand. - The market is projected to nearly double as stroke incidence rises and more patients become eligible for endovascular treatment. What happened: - Market Research Future projected the global neurovascular devices market will rise from $5.56 billion in 2026 to $10.48 billion by 2035. - The forecast implies an 8.22% CAGR for 2026–2035. - The market base was estimated at $5.17 billion in 2025. - The forecast was published June 15, 2026. The details: - The AHA/ASA expanded the mechanical thrombectomy treatment window from 6 hours to 24 hours for select large-vessel occlusion patients. - That change approximately tripled the eligible procedure pool in the United States. - Hospital systems that invested in stroke therapy equipment reported a 22% year-over-year rise in thrombectomy cases in the first full year after implementation. - CMS finalized Medicare coverage for carotid artery stenting across a broader range of clinical conditions in early 2024. - The Medicare policy is expected to add about $320 million in incremental procedure spending by 2028. - Japan’s National Health Insurance expanded coverage for endovascular neurology devices used to treat intracranial stenosis. - More than 400 stroke hospitals in Japan are expected to see procurement gains from that coverage expansion. - Robotic catheter navigation platforms from Corindus and Stereotaxis have been deployed in more than 120 neuro-interventional suites globally. - Those platforms reduced fluoroscopy time by an average of 38% and operator radiation exposure by 52%. - AI-powered stroke triage platforms such as RapidAI and Viz.ai are cutting door-to-puncture times by 20 to 30 minutes. - The NIH allocated more than $410 million to stroke-related neuroscience research in fiscal 2024. - An estimated $2.8 billion in cumulative venture investment went to next-generation stroke treatment devices between 2022 and 2025. - More than 1,800 Joint Commission-certified stroke centers operate in North America. - China’s 14th Five-Year Plan is supporting stroke-ready hospital infrastructure investment. Between the lines: - The market is moving from a niche device category to a system-level stroke-care platform tied to imaging, robotics and software. - Expanded reimbursement and longer treatment windows lower the barrier for hospitals to buy and use neurovascular devices. - The competitive edge is shifting toward companies that can pair catheter platforms with AI workflow tools and robotic navigation. - Asia-Pacific is emerging as the fastest-growing regional demand center because public infrastructure spending is expanding treatment capacity. What’s next: - Asia-Pacific is projected to grow at 9.28% CAGR from 2026 to 2035. - North America remained the largest regional market in 2025 with about 47.2% share. - Europe was the second-largest region in 2025 with about 25.8% share. - Hospitals remained the dominant end user in 2025 with 63.0% share. - Ambulatory surgical centers are projected to be the fastest-growing end-user channel at 9.37% CAGR. - Aneurysm coiling and embolization devices held the largest product share in 2025 at about 34.8%. - Neurothrombectomy devices are projected to be the fastest-growing product category at 9.14% CAGR. - Ischemic stroke was the largest disease segment in 2025 with 53.5% share. - Cerebral aneurysm was the fastest-growing disease indication at 8.86% CAGR. - The WHO projects a 25% rise in global stroke incidence between 2025 and 2035, which supports long-term device demand. The bottom line: - The neurovascular devices market is entering a decade of growth driven by more patients eligible for treatment, better reimbursement and faster adoption of robotic and AI-enabled stroke-care tools.